ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2020

Metabolic Changes Induced by Anti-Malondialdehyde Antibodies Promote Osteoclast Development

Koji Sakurabas1, Akilan Krishnamurthy 2, Cheng Xu 3, Khaled Amara 4, Vivianne Malmström 4, Sergiu-Bogdan Catrina 3, Caroline Grönwall 4, Bence Rethi 5 and Anca Catrina 6, 1Rheumatology unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Solna, stockholm, Sweden, 2Rheumatology unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Solna, Stockholm, 3Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 4Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, 5Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, 6Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoantibodies, mechanisms and monoclonal antibodies, osteoclastogenesis, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Etiology & Pathogenesis Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Malondialdehyde (MDA) is highly reactive compound produced by lipid-peroxidation in situations associated with oxidative stress. MDA can irreversibly modify proteins (e.g. lysine, arginine and histidine residues), which can lead to the generation of immunogenic neo-epitopes that are recognized by autoantibodies. In fact, anti-MDA IgG antibodies are significantly increased in the serum of patients with autoimmune diseases, such as rheumatoid arthritis (1). Recently, anti-MDA IgG antibodies have been shown to promote osteoclast (OC) differentiation in vitro (1). In this study, we decided to further elucidate the molecular mechanisms triggered by these autoantibodies during osteoclastogenesis.

Methods: OCs were generated from monocyte-derived macrophages in the presence of the cytokines RANK-L and M-CSF. The development of OCs was monitored by light microscopy following tartrate-resistant acid phosphatase (TRAP) staining. Three different recombinant human monoclonal anti-MDA antibodies, generated by single-cells cloning from synovial RA B cells, or control antibodies were added to OC cultures. Cellular metabolism was monitored using Seahorse XF Analyzer (extracellular acidification rate and oxygen consumption) and a colorimetric L-Lactate assay. Genes expressions were assessed by RT-PCR.

Results: Lactic acid production correlated with stimulatory effect of anti-MDA antibodies on OCs, suggesting an antibody-mediated regulation of glycolysis. Moreover, extracellular acidification rate and oxygen consumption of the developing OCs were increased by the osteoclastogenic anti-MDA clone but not by control antibodies. We have also observed the upregulation of genes encoding the glucose transporter GLUT1 and the down-regulation of the pyruvate dehydrogenase kinase (PDK)2 and PDK4 enzymes by anti-MDA antibodies. The glycolysis inhibitor 2-deoxyglucose eliminated the stimulatory effect of anti-MDA clone on OCs at drug concentrations that did not influence baseline OC development.

Conclusion: Our study further confirmed that IgG autoantibodies against MDA/MDA-acetaldehyde posttranslational modifications might have pathological roles in RA. We showed that certain anti-MDA clones induced an early boost of glycolysis and mitochondrial respiration in developing OCs and these metabolic changes led to an increased OC differentiation. Our study thus described a new type of autoantibody-induced cellular mechanism that can contribute to bone abnormalities.

Reference: (1) C. Grönwall et al. Journal of Autoimmunity 84 (2017) 29-45.


Disclosure: K. Sakurabas, None; A. Krishnamurthy, None; C. Xu, None; K. Amara, None; V. Malmström, None; S. Catrina, None; C. Grönwall, None; B. Rethi, None; A. Catrina, None.

To cite this abstract in AMA style:

Sakurabas K, Krishnamurthy A, Xu C, Amara K, Malmström V, Catrina S, Grönwall C, Rethi B, Catrina A. Metabolic Changes Induced by Anti-Malondialdehyde Antibodies Promote Osteoclast Development [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/metabolic-changes-induced-by-anti-malondialdehyde-antibodies-promote-osteoclast-development/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/metabolic-changes-induced-by-anti-malondialdehyde-antibodies-promote-osteoclast-development/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology